Latest RIDGEFIELD Stories

Results from RELY-ABLE®, the RE-LY® extension study, support long-term safety of PRADAXA 150mg twice daily in patients with non-valvular atrial fibrillation RIDGEFIELD, Conn., June 14, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the RELY-ABLE(®) trial, a long-term extension of the pivotal RE-LY(®) study of Pradaxa(®) (dabigatran etexilate mesylate) capsules in patients with non-valvular atrial fibrillation (NVAF). PRADAXA is the...

FAIRFIELD, Conn., June 3, 2013 /PRNewswire/ -- PowerBridge, LLC has announced that its affiliate, Hudson Transmission Partners, LLC ("HTP"), has completed testing of its underground and underwater, 660 Mw electric transmission project between Ridgefield, New Jersey and Manhattan, and has begun delivering power to customers in New York City. (Photo: http://photos.prnewswire.com/prnh/20130603/NE24515 ) The Hudson transmission project route has a total length of about 7.5 miles, with a...

U.S.D.O.E. awards research grant to geothermal solar hybrid system. RIDGEFIELD, Wash., May 30, 2013 /PRNewswire-iReach/ -- Geothermal solar hybrid retrofit project receives Department of Energy Grant Approval Marc Rappaport of Rappaport Energy Consulting LLC received notification the US Department of Energy (USDOE) approved a Small Business Innovative Research (SBIR) Phase 1 grant proposal for $ 149,900. The research will study the differential data from retrofitting a...

Boehringer Ingelheim also presents new data from a Phase 2 study demonstrating increased bronchodilation with 5 mcg tiotropium as an add-on therapy in symptomatic patients with moderate persistent asthma at the American Thoracic Society International Conference (ATS 2013) RIDGEFIELD, Conn., May 21, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of...

Data on investigational compounds and an approved product will be presented RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler®...

Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray will become the only available short-acting bronchodilator offering two different medicines in a single inhaler RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and patients that the transition to...

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 - are from Boehringer Ingelheim's robust...

RIDGEFIELD, Conn., April 30, 2013 /PRNewswire/ -- Northern Tier Energy LP (NYSE: NTI), a Delaware limited partnership ("Northern Tier Energy" or the "Partnership"), announced today the pricing of an underwritten public offering of 12,000,000 common units representing limited partner interests in the Partnership (the "Offering") held by Northern Tier Holdings LLC (the "Selling Unitholder") at a price to the public of $26.28 per unit. The common units are being sold in the Offering...

RIDGEFIELD, Conn., April 30, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced three important updates to the U.S. prescribing information for PRADAXA, an oral anticoagulant (OAC) indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The PRADAXA label now carries a Boxed Warning, similar to the Boxed Warnings in the labels of other new OACs, to advise patients that discontinuing treatment...

RIDGEFIELD, Conn., April 29, 2013 /PRNewswire/ -- Northern Tier Energy LP (NYSE: NTI), a Delaware limited partnership ("Northern Tier Energy" or the "Partnership"), announced today that it has commenced an underwritten public offering of 10,000,000 common units representing limited partner interests in the Partnership (the "Offering") held by Northern Tier Holdings LLC (the "Selling Unitholder"). The common units are being sold in the offering pursuant to a registration statement on...